Raises FY25 revenue view to $1.200B-$1.280B from $1.150B-$1.225B. Consensus is for FY25 EPS $5.00 and for revenue $1.19B. Raises FY25 adjusted EBITDA view to $790M-$840M from $755M-$805M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics (HALO) Q1 Earnings Cheat Sheet
- Halozyme: Argenx received positive CHMP opinion for VYVGART with ENHANZE
- Halozyme’s Legal Battle with Merck: A Potential Catalyst for Stock Upside
- Halozyme sues Merck for patent infringement over subcutaneous Keytruda
- Johnson & Johnson’s Darzalex with Halozyme’s Enhanze granted EU approval